Effectiveness of dry needling versus placebo on gait performance, spasticity, electromyographic activity, pain, range-of-movement and quality of life in patients with multiple sclerosis: a randomized controlled trial protocol

Dry needling (DN) is an emerging technique commonly used in neurological and musculoskeletal pain conditions, but there have been no previous studies in patients with multiple sclerosis (pwMS). This trial aims to assess the e_cacy of deep DN, compared with sham placebo DN, on gait performance, spast...

Descripción completa

Detalles Bibliográficos
Autores: Luque Moreno, Carlos, Granja Domínguez, Anabel, Moral Muñoz, Jose A., Izquierdo Ayuso, Guillermo, Lucena Antón, David, Heredia Rizo, Alberto Marcos
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/104943
Acceso en línea:https://hdl.handle.net/11441/104943
https://doi.org/10.3390/brainsci10120997
Access Level:acceso abierto
Palabra clave:Multiple sclerosis
Gait disorders
Neurologic
Pain management
Muscle spasticity
Physical therapy modalities
Dry needling
Clinical trial protocol
Descripción
Sumario:Dry needling (DN) is an emerging technique commonly used in neurological and musculoskeletal pain conditions, but there have been no previous studies in patients with multiple sclerosis (pwMS). This trial aims to assess the e_cacy of deep DN, compared with sham placebo DN, on gait performance, spasticity level, pain, electromyographic activity, range-of-movement (ROM) and quality of life in pwMS. Forty adults with MS were randomly assigned to one study group. The DN group will undergo 2 sessions (once per week) usingDNover the rectus femoris (RF) and gastrocnemius medialis (GM) muscles at the lower extremity with higher spasticity. The placebo group will receive the same protocol using a sham placebo needle (Dong Bang needle). Outcome measures will include gait performance, using the GaitRite® system, spasticity level with the Modified Ashworth Scale, superficial electromyographic activity of RF and GM, pain (pressure algometer), ROM (goniometer), and quality of life (Musiqol). This study is the first investigating the short-term e_ect of DN, compared with placebo, in pwMS, and taking into account the possible changes in the electromyographic activity of the lower limb. Therefore, the results may help to understand the suitability of using this technique in the clinical setting for this population. Trial registration: ACTRN12619000880145.